GlobeNewswire·Nov 19, 2025, 8:30 AM ET

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

Minerva Neurosciences appointed Dr. Inderjit Kaul, currently Chief Medical Officer of Draig Therapeutics, to its board of directors.
Dr. Kaul will also serve as a consultant for the future clinical development of roluperidone.
The appointment follows a recent private placement raising up to $200 million to fund a confirmatory Phase 3 trial for roluperidone.
The funding supports the resubmission of a New Drug Application & preparation for a US commercial launch if approved.
Dr. Kaul previously led the development of Cobenfy at Bristol Myers Squibb & Karuna Therapeutics, resulting in FDA approval for schizophrenia.
Dr. Kaul holds an M.D. & an MPH from Harvard University & has expertise in neurology, oncology, & immunology.
The company aims to address the unmet medical need for treating primary negative symptoms in schizophrenia, which lack FDA-approved therapies.
Forward-looking statements regarding trial outcomes, funding sufficiency, & regulatory approvals are subject to risks & uncertainties.